303 results about "Premalignant Neoplasm" patented technology

KLRB1 binding agents (in particular anti-KLRB1 antibodies and antigen binding portion thereof) and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, INKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.

Treatment of damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) is provided by delivering specialized pulsed electric field energy to target tissue areas in a specific dose so as to obtain a superior outcome. The specialized PEF energy and delivery has been optimized to provide advanced treatment of target tissue areas, including destruction of undesired tissue and generation of improved inflammatory and immune responses. The specialized PEF energy provides superior outcomes to radiofrequency ablation and irreversible electroporation.

Provided are a T-cell receptor (TCR) and the use thereof, wherein the TCR contains an α chain containing a variable region and / or a β chain containing a variable region. The TCR is capable of specifically recognizing an A1101-restricted KRASG12V mutation and an A1101-restricted KRASG12D mutation. A T cell transducing the TCR (TCR-T) can bind to an antigen short peptide-HLA-A1101 complex, and can be used for treating malignant tumors carrying the KRASG12V mutation and KRASG12D mutation.

KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.

Treatment of damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) is provided by delivering specialized pulsed electric field (PEF) energy to target tissue areas in a specific dose so as to obtain a superior outcome. The PEF energy and delivery has been optimized to provide advanced treatment of target tissue areas, including destruction of undesired tissue and generation of improved inflammatory and immune responses. These various types of treatment are controlled by a variety of factors including the electrode geometry, the dose of PEF energy delivered, the time the energy is delivered over, and the waveform of the PEF energy itself. The PEF energy is delivered in the form a dose which is considered to be one application of the specialized energy. Each dose creates a lesion in the target tissue area.

The invention discloses an application of a small molecular compound LZ-A4 in preparation of a preparation or a medicine for treating malignant tumors. The chemical formula of the small molecule compound LZ-A4 is C19H11Cl2N3O3S, and the small molecule compound LZ-A4 can promote degradation of LGMN in malignant tumor cells, inhibit proliferation of tumor cells and inhibit polarization of macrophages to M2 type. The research on a colorectal cancer mouse transplantation tumor model proves that the development of the colorectal cancer can be effectively inhibited by single treatment of the LZ-A4, and the volume of the tumor can be further reduced after the LZ-A4 is combined with a clinical first-line chemotherapeutic drug Oxaliplatin for the colorectal cancer. Meanwhile, the LZ-A4 can inhibit M2 type polarization of macrophages in a tumor microenvironment in vivo, promote infiltration of cytotoxic T cells, remodel the tumor microenvironment and activate anti-tumor immunity. In addition, the A4 has good toxic and side effects, and does not cause further reduction of the body weight of the mouse after being combined with chemotherapeutic drugs.

The invention discloses a digestive tract malignant tumor metastasis risk assessment method and system based on artificial intelligence, and relates to the field of digestive tract malignant tumor metastasis risk assessment. The method comprises the following steps: firstly, acquiring PET-CT three-dimensional image data of a colorectal cancer patient, and constructing and extracting a three-dimensional voxel matrix of a liver region according to the PET-CT three-dimensional image data; inputting the voxel matrix of the liver region into a pre-trained convolutional neural network model, and outputting a probability distribution matrix of each voxel; setting a basic confidence threshold of the malignant tumor metastasis, and extracting candidate focuses according to the probability distribution matrix and the confidence threshold of the malignant tumor metastasis; obtaining the maximum diameter of the candidate focus, dynamically and adaptively adjusting the confidence coefficient threshold value of the malignant tumor metastasis focus according to the maximum diameter, and generating a binary mask matrix; calculating a comprehensive risk score of colorectal cancer liver metastasis according to the binary mask matrix and grading; according to the invention, the false positive inhibition capability can be enhanced and the risk assessment accuracy can be improved.

The invention relates to a heterocyclic compound and application thereof.The structure of the heterocyclic compound is shown as a formula (I) or a formula (II), experiments prove that the heterocyclic compound can efficiently degrade CK1alpha through a molecular glue mechanism, so that a p53 pathway, a Wnt / beta-catenin pathway, an ATM pathway and the like are affected, and the heterocyclic compound can be used for preventing or treating diseases caused by abnormally high expression of CK1alpha, and can be used for treating diseases such as diseases caused by abnormally high expression of CK1alpha. The compound can be used for preparing medicines for treating malignant tumors and solid tumors of a blood system, especially medicines for treating acute myeloid leukemia.

Benfo-oxythiamine (B-OT) and / or oxythiamine (OT) are administered as active substances concurrently with ongoing radionuclide therapy (RNT), particularly radioimmunotherapy (RIT) and / or radiopeptide or radioligand or radiopeptide ligand therapy (RLT), in the treatment of patients with tumors, especially malignant tumors. B-OT and / or OT administration is cyclical, meaning that phases of B-OT and / or OT administration ("B-OT / OT administration cycles") alternate with treatment breaks (administration breaks). In each B-OT / OT administration cycle, B-OT and / or OT is administered on one or more consecutive days at a predetermined dose (mg per kg of the patient's body weight). This is followed by a treatment break in which neither B-OT nor OT is administered, and then the next B-OT / OT administration cycle.

The invention relates to an application of a compound and a pharmaceutical composition thereof in preparation of a medicine for treating anemia of patients with non-myeloid malignant tumors subjected to chemotherapy, and the compound is N-[7-hydroxy-5-(2-phenethyl) [1, 2, 4] triazole [1, 5-a] pyridine-8-carbonyl] glycine.

Provided is a method of treating malignant tumor by an azabicyclic compound, particularly, with eye disorder reduced. The present invention provides a method for treating malignant tumor, comprising administering an effective amount of 3-ethyl-4-[3-(1-methylethyl)-4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-1H-pyrazolo[3,4-b]pyridin-1-yl]benzamide (compound 1) or a salt thereof to a patient in need thereof according to a dosing regimen, wherein the dosing regimen comprises administering the compound 1 or the salt thereof at a dose from 40 mg / body / day to 240 mg / body / day in terms of the amount of the compound 1 for consecutive days, and then providing a withdrawal period of at least 2 days.

Methods for prognosticating if an individual afflicted with a malignant tumor is likely to respond favorably to immunotherapy comprising testing for the presence or absence of DARC expression in the tumor, and if no DARC expression is detected, identifying the individual as not being suitable for immunotherapy, and optionally administering an anti-cancer therapy other than immunotherapy to the individual, or if DARC expression is detected, then identifying the individual as being suitable for immunotherapy, and optionally administering immunotherapy or any other anti-cancer therapy to the individual.

Therapeutic compositions comprising chitosan-derived compositions are useful agents when administered in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.

The invention discloses bionic nanoparticles, a composition, a preparation method and application thereof, and relates to the technical field of red blood cell-cancer cell hybrid membrane bionics. The bionic nanoparticles comprise lipidosome and a hybrid membrane coated on the surface of the lipidosome, drugs are coated in the lipidosome, and the drugs are astragaloside and curcumin; the molar ratio of the medicine to the liposome is 1: 15; the hybrid membrane is a hybrid membrane of an erythrocyte membrane and a cancer cell membrane. The erythrocyte-cancer cell hybrid membrane wraps the outer layer of the liposome phospholipid bilayer to construct the nano targeting drug delivery system, the modification of the hybrid cell membrane integrates the advantages of long circulation, immune escape, homologous targeting and the like, and a new treatment mode is developed for immunotherapy of malignant tumors with low response rate. The hybrid membrane can improve the targeting property of the drug, reduce side effects on patients and improve the tolerance of the patients. The medicine can be coated in an aqueous solution layer of the liposome, so that the water solubility of the medicine is improved, and meanwhile, the anti-tumor effect of the medicine can be enhanced.

Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

The present invention relates to third-generation CAR-CD30 T cells for the treatment of CD30+ tumors such as lymphoid malignancies, leukemias, and solid tumors.

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

This invention provides the application of Jiawei Xihuang Pill (MXHP) in the preparation of drugs for the prevention and / or treatment of malignant tumors. This invention also provides the application of Jiawei Xihuang Pill in combination with chemotherapy drugs for the prevention and / or treatment of malignant tumors, particularly glioblastoma multiforme (GBM), wherein the active ingredients of Jiawei Xihuang Pill are prepared from bezoar, musk, vinegar-processed frankincense, vinegar-processed myrrh, and Panax notoginseng root extract in a weight ratio of 14-16:14-16:545-555:545-555:245-255. MXHP can synergistically inhibit the growth of glioblastoma in situ and induce tumor cell apoptosis, indicating that MXHP may be a potential therapeutic drug. Furthermore, compared to XHP, MXHP significantly prolongs the median survival of GBM, exhibiting an enhanced anti-GBM effect.

The present invention relates to a GPC3xCD3 bispecific antibody, a GPC3xCD28 bispecific antibody, and a combination of two agonistic fully human κλ antibodies, one targeting GPC3xCD3 and the other targeting GPC3xCD28, both of which do not compete for binding to GPC3. The present invention also relates to the use of the bispecific antibodies for the treatment of GPC3-positive malignancies.

The invention belongs to the field of molecular biology, particularly relates to the field of tumor treatment, and particularly relates to application of a TRK inhibitor LYS-8 in preparation of a medicine for treating malignant tumors, particularly pancreatic cancer. LYS-8 is a small molecule TRK inhibitor with a novel structure, and research finds that LYS-8 can significantly inhibit TRK kinase activity and down-regulate downstream PI3K-AKT and other signal channels. Experimental results show that the inhibition effect of LYS-8 in pancreatic cancer cells is obviously superior to that of colorectal cancer cells, and the IC50 value of LYS-8 is lower; in an animal model, the tumor inhibition rate of LYS-8 on pancreatic cancer reaches about 70%, and the inhibition rate on colorectal cancer is about 56%, which is obviously superior to that of a colorectal cancer model. The invention reveals that LYS-8 has an unexpected curative effect advantage on pancreatic cancer, and a new drug choice is provided for targeted therapy of pancreatic cancer.

The disclosure belongs to the technical field of medicine. Provided are a CD97 and GSDME interaction inhibitor having anti-tumor activity and an application thereof. A compound screened in the disclosure enhances the susceptibility of NK cells to kill tumor cells by inhibiting the interaction between GSDME and CD97 in tumor cells, so as to induce an immune anti-tumor effect. Moreover, the compound enhances the susceptibility of tumor cells to pyroptosis by blocking the protective effect of CD97 on cleavage of GSDME proteins. Therefore, the compound can be used for treating GSDME and CD97 double-positive malignant tumors, and combined chemotherapy, immunotherapy, etc., to enhance the susceptibility of malignant tumors to chemotherapy and immunotherapy, prolonging the overall survival period of patients with malignant tumors. Specifically provided is a compound having a structure set forth in formula (I), a pharmaceutically acceptable salt, a solvent compound or a deuterated compound thereof.

The present disclosure relates to methods and uses of anti-HER2 antibody drug conjugates for treatment of gynecological malignant tumors. Specifically, the invention relates to application of the anti-HER2 antibody drug conjugate in preparation of drugs for treating gynecological malignant tumors expressed by HER2, and the structure of the antibody drug conjugate is shown as a formula (I). # imgabs0 #

The present disclosure describes the use of an anti-insulin receptor antibody to treat neoplasms and / or tumor-associated hyperinsulinism and resulting hypoglycemia caused by benign or malignant neoplastic production of insulin and / or other effector substances (e.g., IGF-2 or its variants) that interact with the INSR and thus result in insulin-like action.

This invention discloses a PROTAC chimera for targeted degradation of ALKBH5, its preparation method, and its applications. The structural formula of the PROTAC chimera is shown in Formula I. The PROTAC chimera provided by this invention achieves specific ubiquitination modification and proteasome-dependent degradation of the ALKBH5 protein, completely eliminating the target protein function from its source. This invention overcomes the inherent limitations of traditional small molecule inhibitors, which can only reversibly block ALKBH5 enzyme activity, cannot eliminate the target protein, easily induce compensatory upregulation of the target protein, and develop drug resistance. It provides a novel and precise targeted therapy strategy for ALKBH5-driven malignant tumors.

The invention discloses an application of a small molecule compound C2 in preparation of a preparation or a medicine for treating malignant tumors. The molecular formula of the small molecule compound C2 is C25H27N3O4S, and the small molecule compound C2 can significantly promote degradation of PD-L1 in triple negative breast cancer cells and enhance tumor immune response. The research on a triple negative breast cancer mouse transplantation tumor model proves that the small molecule compound C2 can obviously enhance the infiltration of immune cells in a tumor microenvironment and inhibit tumor growth, and shows a good treatment effect on malignant tumors.

The invention relates to a medical instrument for gynecologic operation, in particular to a uterus traction device capable of avoiding tumor cell diffusion and a using method thereof.The traction device comprises a bag, the bag is provided with a closed end used for wrapping the bottom of the uterus and an open end used for facing the cervix uteri opening, and the bag is provided with an opening. The open end is provided with an adjusting and tightening mechanism, the cervix uteri, the uterus body and the double accessories of the cervix uteri and the uterus body can be wrapped in the bag by pulling the open end, and then the open end is tightened through the adjusting and tightening mechanism. A wrapping path in the direction from the bottom of the uterus to the cervix uteri opening is adopted, it is ensured that the uterus and contents of the uterus are completely wrapped and isolated in the bag by tightening the opening end, the operation concept that isolation is carried out in advance is achieved, the operation view is protected in the whole process, and tumor-free traction in the operation process is facilitated; in addition, the risks of incision planting and abdominal cavity spreading in malignant tumor surgery can be greatly reduced, the possibility of tumor cell spreading is avoided, and iatrogenic injury is reduced.

The invention relates to the field of preparation of CD19 targeted CAR-T cells, in particular to an adjustable CD19 targeted CAR-T cell preparation technology which comprises the following operation steps: S1, T cell collection and separation: S1.1, peripheral blood collection: blood is collected from peripheral veins of a patient, and the general collection amount is determined according to the physical condition of the patient and the amount required by subsequent cell culture and is usually between 50ml and 500ml; s1.2, performing density gradient centrifugal separation on the T cells; s2, CAR gene construction and carrier preparation: S2.1, CAR structure design (taking an inducible promoter system as an example), CD19 targeting CAR-T cells can accurately recognize and combine CD19 antigens on the surfaces of tumor cells, and as CD19 is highly expressed on the surfaces of most blood system malignant tumor cells such as B cell lymphoma and leukemia and is limited in expression in normal tissue cells, the CD19 targeting CAR-T cells can be used for accurately recognizing and combining the CD19 antigens on the surfaces of the tumor cells. Therefore, the CAR-T cells can specifically attack tumor cells like a'biological missile ', and damage to normal tissues is reduced.

To provide a therapeutic agent enabling treatment of a malignant tumor.SOLUTION: A therapeutic agent comprising a substance that recognizes a target expressed in an erythroblast, where the therapeutic agent is administered such that, during a dosing period, a serum concentration of the substance in a subject administered with the therapeutic agent is maintained at 10% or more of a maximum value after administration.SELECTED DRAWING: None

Disclosed in the present invention are nitrogen-containing compounds as well as a preparation method therefor and the use thereof. Specifically disclosed in the present invention are compounds shown as formula I or pharmaceutically acceptable salts thereof, which have one or more of the following advantages: accurate targeting of tumor cells, long tumor retention and inhibition time, and capability of being safely used for malignant tumor diagnosis, staging and / or treatment.

The present invention belongs to the technical field of medicine, and specifically relates to the use of a compound as represented by the following formula (I) or a pharmaceutically acceptable salt, isomer, or crystal form thereof in the preparation of a drug for preventing or treating malignant B cell tumors.